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Abstract Anaphylaxis due to Hymenoptera stings is one of
the most severe consequences of IgE-mediated hypersensitiv-
ity reactions. Although allergic reactions to Hymenoptera
stings are often considered as a general model for the under-
lying principles of allergic disease, diagnostic tests are still
hampered by a lack of specificity and venom immunotherapy
by severe side effects and incomplete protection. In recent
years, the knowledge about the molecular composition of Hy-
menoptera venoms has significantly increased and more and
more recombinant venom allergens with advanced character-
istics have become available for diagnostic measurement of
specific IgE in venom-allergic patients. These recombinant
venom allergens offer several promising possibilities for an
improved diagnostic algorithm. Reviewed here are the current
status, recent developments, and future perspectives of molec-
ular diagnostics of venom allergy. Already to date, it is
foreseeable that component-resolution already has now or will
in the future have the potential to discriminate between clini-
cally significant and irrelevant sensitization, to increase the
specificity and sensitivity of diagnostics, to monitor immuno-
therapeutic intervention, and to contribute to the understand-
ing of the immunological mechanisms elicited by insect
venoms.
Keywords Apis mellifera . Component-resolved diagnosis .
Hymenoptera venom . Insect venom allergy . Recombinant
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Introduction
Allergy to the venom of Hymenoptera species is a classical
IgE-mediated allergic disease caused by the crosslinking of
receptor-bound IgE antibodies on the surface of mast cells
and basophils. Hymenoptera venom allergy is one of the
most severe hypersensitivity reactions with regard to the
high risk of anaphylactic reactions with potentially fatal
outcome.
Although venom allergy is one of the most frequent trig-
gers of anaphylactic reactions in adults [1–3], the true number
of fatalities may be underestimated since a study reports the
presence of venom-specific IgE in 23 % of post-mortem se-
rum samples taken from subjects, who had died outdoors sud-
denly and inexplicably between May and November [4]. Ap-
proximately 9.2 to 28.7 % of the adult population shows a
sensitization to Hymenoptera venom [5], and the prevalence
of systemic sting reactions among adults ranges between 0.3
and 7.5 % [5, 6]. A preferential association was observed
between Hymenoptera venom allergy and mastocytosis [7•],
since 20 to 39 % of patients with mastocytosis suffer from
Hymenoptera venom allergy [5, 8, 9]. In addition to the higher
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prevalence of systemic reactions to Hymenoptera venom in
adult patients withmast cell disorders, there are several reports
which suggest that these patients are at risk for more severe
reactions following stings [10–13].
Globally, all allergy-eliciting Hymenoptera belong to the
suborder Apocrita which consists of the superfamilies
Apoidea (Apinae and Bombinae subfamilies) and Vespoidea
(Vespinae, Polistinae, Formicinae, and Myrmicinae subfam-
ilies). In western and central Europe, the predominant elicitors
of venom allergy are stings of honeybees (Apis mellifera) and
yellow jackets (Vespula vulgaris). In southern Europe and the
United States (US), additionally allergic reactions to paper
wasps (Polistinae) are common [14]. In Europe, allergic reac-
tions to ants are rare while they are of great importance in the
US (especially Solenopsis invicta) [15] and Australia (espe-
cially Myrmecia pilosula) [16].
For patients with anaphylactic reactions to Hymenoptera
venom, the only causative treatment which is effective in re-
ducing the risk of subsequent systemic reactions is venom
immunotherapy (VIT). Particularly in Hymenoptera, venom-
allergic patients specific immunotherapy is very effective in
inducing tolerance with a protection rate ranging from 75 to
98 % [17]. Prerequisite for the initiation of VIT should be the
verification of an IgE-mediated reaction against the culprit
venom. An unnecessary treatment with more than one or even
with the wrong venom can lead to de novo sensitizations [18],
increased risk of side effects and missing or limited protection
to further stings and moreover, drastically increases the treat-
ment costs.
The diagnosis of Hymenoptera venom allergy comprises
the past medical history of a systemic sting reaction, a positive
skin test response, and the detection of venom-specific IgE
antibodies. Especially when the patient was not able to defi-
nitely identify the culprit insect, in clinical practice, the correct
diagnosis is not always straightforward due to inherent prob-
lems and limitations of both tests. On the one hand, there are
patients with a convincing history of anaphylaxis but negative
diagnostic tests and, on the other hand, up to 50 % of patients
show positive tests with more than one venom. Moreover, to
date, no molecular tools are available which allow the predic-
tion of the success of venom immunotherapy. Several limita-
tions of diagnostic tests are based on the use of whole venom
preparations for diagnosis. Venom preparations just like many
other allergen extracts such as pollen or mite extracts [19, 20]
often might show a highly variant allergen composition,
which is essentially based on natural variability of the source
material and additionally increased by different processing
modalities or degradation of labile allergens, and in some
cases, underrepresentation of particular allergens of high rel-
evance. Hence, the reliability of diagnostic approaches is ham-
pered by using venom extracts and the variant composition
and low abundance of particular allergens even might affect
therapeutic efficacy.
In recent years, significant progress has been made in the
identification of novel Hymenoptera venom allergens, the de-
tailed characterization of established allergens, and the devel-
opment of suitable strategies for the recombinant production
of venom allergens. To date, analyses on a molecular level are
able to overcome at least some of the problems of diagnostic
approaches and to contribute to an improved therapeutic in-
tervention right now [21, 22••, 23, 24•].
Hymenoptera Venom Allergens
Hymenoptera venoms are complex cocktails of low molecular
weight substances such as biogenic amines, basic peptides,
toxins, and of higher molecular weight proteins, many of them
with enzymatic activity, together with a variety of other com-
ponents, all of which may contribute to sensitization, allergic
symptoms, and success of immunotherapy.
The certainly best characterized venom is that of the hon-
eybee Apis mellifera, which surely is due to the outstanding
importance of beekeeping and thus of the honeybee as elicitor
of venom allergy all over the world and moreover, to the
availability of detailed proteomic data of pure venom [25]
and genomic information of the honeybee [26]. Additionally,
in the last years, much progress has been made in the identi-
fication of new allergens of the yellow jacket (in Europe called
common wasp) Vespula vulgaris. Among the best character-
ized honeybee venom (HBV), allergens are phospholipase A2
(Apim 1), hyaluronidase, (Api m 2) and melittin (Api m 4), all
constitutingmedium to higher abundance proteins [27]. Prom-
inent yellow jacket venom (YJV) allergens include phospho-
lipase A1 (Ves v 1), hyaluronidase (Ves v 2.0101), and antigen
5 (Ves v 5), a protein of unknown function but high abundance
in the venom [28, 29]. Recently, a second inactive hyaluron-
idase (Ves v 2.0201), carrying an inactivating mutation in the
active site of the enzyme, was identified in YJV which inter-
estingly seems to be the predominant isoform [30, 31].
Mainly by proteomic approaches in the last years, much
progress has been made in identifying important allergens of
low abundance. The gene of the well-known acid phosphatase
(Api m 3) of HBVwas identified and recombinantly produced
[27, 32], and with the 100 kDa dipeptidyl peptidases IV (DPP
IV) from HBV (Api m 5) and YJV (Ves v 3), a new class of
homologous and cross-reactive Hymenoptera venom en-
zymes was identified [33]. Additionally, the 200 kDa
vitellogenins Api m 12 and Ves v 6 were described as novel
pair of cross-reactive panallergens of HBV and YJV [34].
Furthermore, it was demonstrated that Api m 10 (Icarapin,
carbohydrate-rich protein) is a species-specific major allergen
of HBVwhich might be of considerable interest for diagnostic
as well as for therapeutic purposes [35••]. Very recently, it was
demonstrated that at least nine additional Api m 10 transcript
isoforms which are generated by alternative splicing or as
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intragenic chimeric transcripts are present in the venom gland
[36]. The IgE reactivity with the Api m 10 isoforms, at least
several of which are present in the venom proteome, is both,
isoform- and patient-specific [36]. Other allergens of HBV
include a putative protease inhibitor (Api m 6) [37, 38], a
protease (Api m 7) [39], an esterase (Api m 8), a peptidase
(Api m 9), and the two major royal jelly proteins (MRJP) 8
and 9 (Api m 11 isoforms) [40]. The role as major allergens to
which more than 50% of patients show IgE reactivity to so far
was demonstrated for the HBV allergens Api m 1, Api m 2,
Api m 3, Api m 5, and Api m 10 [41••]. Although, these five
HBV allergens together with Api m 4 are able to detect IgE
reactivity in approximately 95% of patients with HBVallergy,
the picture might be much more complex since at least 113
proteins and peptides were identified in HBV [42]. Moreover,
the complexity is increased by different glycosylation patterns
and protein heterogeneity [25, 36, 37, 43, 44] and even sea-
sonal effects seem to influence the venom composition [45]. It
can be anticipated that other Hymenoptera venoms will exhib-
it a comparable degree of complexity.
Bumblebee venom closely resembles honeybee venom and
has two allergens of known sequence, phospholipase A2, and
a protease. The honeybee and bumblebee venom phospholi-
pases A2 show extensive sequence identity with each other,
while no sequence identity is given with vespid phospholipase
A1 [46], which differs in its specificity of the catalytic mech-
anism. The bumblebee has gained significantly in importance
since it is increasingly used for pollination in greenhouses
[47]. Similarly, the venoms of hornets, white-faced hornets,
and paper wasps resemble YJV and contain phospholipases
A1, hyaluronidases, and antigens 5, all of them exhibiting a
high degree of sequence similarity. Moreover, fire ant venoms
show high similarity with vespid venoms and contain a phos-
pholipase A1 and an antigen 5. Varying from all other known
Hymenoptera venoms, the major allergens of the Myrmecia
venom are small peptides (pilosulins) which partially form
homo- or heterodimers [48], but additionally, phospholipase
and hyaluronidase activity was reported. A detailed overview
about the presently known Hymenoptera venom allergens is
given in Table 1.
Recombinant Hymenoptera Allergens for Diagnosis
Only few allergens are present in substantial amounts in the
venom. For honeybee venom, for example, Api m 1 and Api
m 4 are predominant with amounts of dry weight of 12 and
50%, respectively. Since low abundance allergens are difficult
to isolate in substantial amounts, their recombinant availabil-
ity can be considered a prerequisite for their detailed charac-
terization and their use for diagnostic applications. However,
even the purification of allergens of higher abundance from
allergen extracts and their subsequent use for diagnosis has
several disadvantages such as the danger of remaining impu-
rities with other allergens and the presence of cross-reactive
carbohydrate determinants (CCDs), both of which might se-
verely impair and falsify analyses on a molecular diagnostic
level.
All these problems can be bypassed by the application of
recombinant technologies. Some allergens have been tradi-
tionally produced in bacteria, but for several venom allergens
produced in this way, conformational IgE epitopes are affected
due to the lack of proper posttranslational modifications and
correct folding. Although, the bacterial system impresses with
its production rates and cost-effectiveness, this recombinant
approach is only feasible for structurally less complex aller-
gens. So far, only the HBVallergen Api m 10 could be easily
produced with authentic IgE reactivity in bacteria [35••]. Oth-
er small allergens produced in the prokaryotic system such as
Api m 1 and Ves v 5 have to be subject to extensive refolding
strategies to sustain comparable IgE reactivity to their native
counterparts [49, 50]. For larger allergens, these strategies
clearly will lead to limitations since for several allergens, post-
translational modifications such as the addition of glycan
structures or correct disulfide bridging are imperative for cor-
rect folding and formation of conformational B cell epitopes.
For such allergens, the recombinant production in eukaryotic
cells from insect origin appears to be superior in terms of
correct folding, glycosylation, and conservation of the full
spectrum of epitopes [31, 33].
In the last decade, insect cell lines have developed to one of
the most appropriate systems for the production of correctly
folded authentic venom allergens [31, 33, 35••, 43, 51–53],
which additionally offer considerable advantages compared to
native allergens (see next paragraph). Moreover, some native
allergens from Hymenoptera venoms such as Api m 1 were
demonstrated to activate effector cells independent of IgE on-
ly by their enzymatic activity, thereby hampering cellular di-
agnostic assays [43, 54–56]. In contrast, recombinant strate-
gies allow the inactivation of such activities without influenc-
ing the IgE reactivity of the allergen [43, 57].
So far, only the major allergens Api m 1 (phospholipase
A2) of HBV, Ves v 1 (phospholipase A1) and Ves v 5 (antigen
5) of YJV, and Pol d 5 (antigen 5) of Polistes dominula venom
are available for routine molecular diagnostics. Ves v 1 and
Ves v 5 in different patient populations allow the identification
of 92 to 96 % of patients with confirmed YJVallergy [58, 59,
60••]. In contrast, sensitivity of Api m 1 for the diagnosis of
HBVallergy is lower and ranges from 58 to 80 % depending
on the selection criteria of the patient population [41••, 61,
62•, 63, 64]. As a consequence of the diagnostic gap, which
is created by using Api m 1 only for molecular IgE diagnos-
tics, additional species-specific major allergens would be
highly desirable. In a recent study, Api m 2, Api m 3, Api m
4, Api m 5, and Api m 10 in addition to Api m 1 were used in
form of ImmunoCAP research prototypes to diagnose 144
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Table 1 Overview of the hymenoptera venom allergens which are presently listed in the WHO/IUIS Allergen Nomenclature official database
Allergen Name/Function MW [kDa] Potential N-glycosylation
American paper wasps (Polistes annularis, P. exclamans, P. fuscatus, P. metricus)
Pol a 1, Pol e 1 Phospholipase A1 34 0
Pol a 2 Hyaluronidase 38 2
Pol e 4 Protease ?
Pol a 5, Pol e 5, Pol f 5, Pol m 5 Antigen 5 23 0
Australian jumper ant (Myrmecia pilosula)
Myr p 1 7.5/5.5 0
Myr p 2 Pilosulin-3 8.5/2.4 0
Myr p 3 Pilosulin-4.1 4 0
Bees (Apis mellifera, A. cerana, A. dorsata)
Api m 1a, Api c 1, Api d 1 Phospholipase A2 16 1
Api m 2 Hyaluronidase 45 3
Api m 3a Acid phosphatase 49 2
Api m 4a Melittin 3 0
Api m 5 Allergen C/DPP IV 100 6
Api m 6 Protease inhibitor 8 0
Api m 7 Protease 39 3
Api m 8 Carboxylesterase 70 4
Api m 9 Carboxypeptidase 60 4
Api m 10a CRP/Icarapin 55 2
Api m 11.0101a MRJP 8 65 6
Api m 11.0201a MRJP 9 60 3
Api m 12 Vitellogenin 200 1
Bumblebee (Bombus pennsylvanicus, B. terrestris)
Bom p 1, Bom t 1 Phospholipase A2 16 1
Bom p 4, Bom t 4 Protease 27 0, 1
European paper wasps (Polistes dominula, P. gallicus)
Pol d 1, Pol g 1 Phospholipase A1 34 1
Pol d 4 Protease 33 6
Pol d 5, Pol g 5 Antigen 5 23 0
Fire ants (Solenopsis invicta, S. geminata, S. richteri, S. saevissima)
Sol i 1 Phospholipase A1 35 3
Sol i 2, Sol g 2, Sol r 2, Sol s 2 14 0
Sol i 3, Sol g 3, Sol r 3, Sol s 3 Antigen 5 26 2
Sol i 4, Sol g 4 12 0
Hornets (Vespa crabro, V. magnifica, V. mandarinia)
Vesp c 1, Vesp m 1 Phospholipase A1 34 0
Vesp ma 2 Hyaluronidase 35 4
Vesp c 5, Vesp ma 5, Vesp m 5 Antigen 5 23 0
Polybia wasp (Polybia paulista, P. scutellaris)
Poly p 1 Phospholipase A1 34 0
Poly s 5 Antigen 5 23 0
White-faced hornet, yellow hornet (Dolichovespula maculata, D. arenaria)
Dol m 1 Phospholipase A1 34 2
Dol m 2 Hyaluronidase 42 2
Dol m 5, Dol a 5 Antigen 5 23 0
Yellow jackets (Vespula vulgaris, V. flavopilosa, V. germanica, V. maculifrons, V. pensylvanica, V. squamosa, V. vidua)
Ves v 1a, Ves m 1, Ves s 1 Phospholipase A1 35 0, 0, 2
Ves v 2.0101, Ves m 2 Hyaluronidase 45 4
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patients with confirmed HBV allergy [41••]. The study dem-
onstrated that not only Api m 1 but also Api m 2, Api m 3, Api
m 5, and Api m 10 are major allergens to which more than
50 % of patients exhibit sIgE reactivity to, thus indicating that
HBV contains a higher number of clinically important aller-
gens than formerly anticipated. The combination of all 6 al-
lergens showed a diagnostic sensitivity of approximately 95%
whereby 74 % of patients were sensitized to more than one
allergen. Interestingly, the patient population showed 39 dif-
ferent sensitization profiles. Most of these allergens are cur-
rently being evaluated for clinical diagnostic use and will,
once approved, provide important new diagnostic tools for
clinicians managing patients with HBVanaphylaxis.
In addition to the added value of recombinant insect venom
allergens in serological IgE diagnosis, also other diagnostic
tests such as the basophil activation test could be improved
by the additional use of recombinant venom allergens, thus
leading to the development of more reliable and efficient
in vitro tests for molecular allergy diagnostics [65].
Molecular Diagnostics for the Dissection of Multiple
Sensitizations
Positive results in skin testing or sIgE testing to conventional
Hymenoptera venom extracts do not always reflect a clinically
relevant sensitization [66]. In clinical practice, up to 50 % of
patients show double-positive test results with honeybee and
yellow jacket venom [67, 68]. In addition to true double sen-
sitization to both venoms, these double-positive results are
frequently caused by clinically irrelevant cross-reactive anti-
bodies to cross-reacting carbohydrate residues. As many pa-
tients are not able to identify the culprit insect, a clinically
relevant sensitization to both venoms cannot be excluded
without further sIgE diagnosis on a molecular level. In the
pre-molecular era, this has often led to an unnecessary treat-
ment with both venoms resulting in higher costs, increased
risk of side effects and possible de novo sensitizations [18].
On the one hand, cross-reactivity may be based on the
recognition of common protein epitopes of homologous aller-
gens, present in both venoms as described for hyaluronidases
(Api m 2 and Ves v 2), dipeptidyl peptidases (Api m 5 and Ves
v 3) and vitellogenins (Api m 12 and Ves v 6) [33, 34]. On the
other hand, the majority of cross-reactivities can be attributed
to IgE antibodies that are directed against cross-reactive car-
bohydrate determinants (CCDs) (Fig. 1a, b) [69, 70]. This is of
particular importance, since most Hymenoptera venom aller-
gens are glycoproteins with one or more of such carbohydrate
structures (Table 1). In insects, the relevant CCD epitope is
defined by an alpha-1,3-linked fucose residue at the innermost
N-acetylglucosamine of the carbohydrate core structure
(Fig. 1a). Plants additionally carry a beta-1,2-xylose as second
immunogenic modification. Since both glycan modifications
are not present on human carbohydrate structures, they are
highly immunogenic and can induce the production of specific
IgG and IgE antibodies in humans [71]. IgE antibodies with
specificity for the alpha-1,3-fucose epitope are responsible for
approximately 75% of double sensitizations to HBVand YJV
[72]. The clinical relevance of these IgE antibodies appears to
be rather low; however, they clearly affect diagnostic ap-
proaches since they cause multiple reactivities with any
insect- or plant-derived glycoproteins. Thereby, CCD-
specific IgE antibodies prevent the elucidation of clinically
relevant sensitizations to protein epitopes and complicate the
choice of the correct venom for immunotherapy (Fig. 1b). For
the detection of the presence of CCD-specific IgE, nowadays,
different reagents (ascorbate oxidase, bromelain, horseradish
peroxidase, MUXF) have become available. However, since
specific IgE directed against both, CCD and protein epitopes
might be present, the detection of CCD-specific IgE does not
allow the exclusion of sensitization to protein epitopes of mul-
tiple venoms [73]. So far, the only exceptions are the venoms
of the paper wasps (Polistinae) which show no immunologi-
cally detectable CCD-reactivity [74].
Nowadays, molecular diagnostics using recombinant aller-
gens has remarkable potential to discriminate between
protein- and CCD-based IgE reactivity (Table 2). The use of
Spodoptera frugiperda (Sf9) insect cells allows the recombi-
nant production of properly glycosylated and thus correctly
folded but CCD-free allergens due to a lack of immunologi-
cally detectable alpha-1,3-core fucosylation [31, 35••, 40, 43].
The advantage of CCD-free allergens is well illustrated by a
Table 1 (continued)
Allergen Name/Function MW [kDa] Potential N-glycosylation
Ves v 2.0201 Hyaluronidase (inactive) 45 2
Ves v 3 DPP IV 100 6
Ves v 5a, Ves f 5, Ves g 5, Ves m 5, Ves p 5, Ves s 5, Ves vi 5 Antigen 5 25 0
Ves v 6 Vitellogenin 200 4
Allergens which are available for routine molecular diagnostics or most likely will become available in 2015 are printed bold
CRP carbohydrate-rich protein, DPP IV dipeptidyl peptidase IV, MRJP major royal jelly protein
aMarker allergens with experimental evidence to be able to discriminate each by itself between honeybee and yellow jacket venom allergy
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comparison of native and recombinant CCD-free HBV major
allergen Api m 1 [62•]. Both show a comparable diagnostic
performance for CCD-negative patients. In contrast, for CCD-
positive patients, native Api m 1 shows an increased reactivity
only due to the CCD-reactivity of the native allergen, thereby
demonstrating the superior performance of CCD-free aller-
gens for CCD-positive patients. Moreover, the use of
species-specific CCD-free allergens facilitates the exclusion
of cross-reactivity due to protein epitopes of homologous al-
lergens present in HBVand YJV.
Fig. 1 Molecular sIgE diagnostics: avoidance of glycan-specific binding
and increased assay sensitivity. a Schematic representations of the core
glycosylation of humans and insects. The latter carries an additional
alpha-1,3-fucose residue which is not present in human carbohydrate
structures and therefore is highly immunogenic. It can induce
the generation of cross-reactive human IgE antibodies. (GlcNAc,
N-acetylglucosamine; man, mannose; fuc, fucose). b Molecular
diagnostics with recombinant marker allergens are able to exclude
“false-positive” test results due to IgE directed against cross-reactive
carbohydrate determinants (CCDs) or homologous allergens present in
venom extracts. Thus, the detection of true sensitizations is markedly
improved. c Molecular diagnostics with recombinant allergens is able to
uncover IgE sensitizations to allergens that are underrepresented, labile,
degraded, or masked in venom extracts and thereby helps to avoid “false-
negative” test results
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Taken together, in most cases where the extract-based di-
agnostics does not allow the identification of the culprit ven-
om due to clinically irrelevant cross-reactivity, the analysis on
a molecular level applying species-specific venom allergens,
devoid of CCDs, enables the detailed characterization of sen-
sitization profiles and the identification of the venom causing
clinical symptoms (Fig. 1b and Table 2) [59, 61, 64, 75, 76,
77••].
However, in the coming years, the field of molecular IgE
diagnostics for the elucidation of multiple sensitization to Hy-
menoptera venoms will face additional challenges that need
better solutions. In addition to their established importance in
North America and Mediterranean regions of Europe, paper
wasps, especially Polistes dominula, increasingly spread all
over Europe as well as in the US from the warmer to the more
moderate climate zones. Cross-reactivity between Polistinae
and Vespinae (especially Vespula species) venoms is frequent-
ly observed [14, 78] independent of CCD-reactivity [74]. For
Polistes venoms, only a very limited number of allergens is
described, all of which are highly homologous to Vespinae
allergens. Although it was proposed that Polistes and Vespula
venom allergy should be discriminated by measurement of
sIgE to antigens 5 (Pol d 5 and Ves v 5) and phospholipases
(Pol d 1 and Ves v 1) [14], the known degree of sequence
homology does not rule out extensive sIgE cross-reactivity
based on protein epitopes. Thus, this approach only allows
an estimation of the probably sensitizing venom. Moreover,
the proposed discrimination relies on the amount of sIgE to
the allergens of the different species. This is a factor which can
depend on other causes than primary sensitization, such as
quality of the allergen used for sIgE testing, and in many
cases, results will be difficult to interpret. Thus, there is clearly
a need for the identification and characterization of additional
species-specific marker allergens for a more reliable
diagnosis.
Molecular Diagnostics in Patients With Undetectable
Sensitization
Another diagnostic problem arises in patients with a convinc-
ing history of a systemic sting reaction but undetectable spe-
cific IgE in classical extract-based diagnostic approaches. A
prominent example is a study comprising 308 patients with a
systemic reaction to a yellow jacket sting [60••]. Only 83.4 %
of the patients showed sIgE to the conventional YJV extract
ImmunoCAP. In contrast, using the individual allergens Ves v
1 and Ves v 5, a sensitization was verified in 96 % of the
patients. Interestingly, among the extract-negative patients,
only one was tested positive for Ves v 1, whereas 84.4 %
(42/51) showed a positive test with Ves v 5. Moreover, and
in contrast to Ves v 1, in most extract-positive patients, the
level of sIgE to Ves v 5 was substantially higher than the level
to YJV extract, suggesting an underrepresentation of Ves v 5
epitopes in the extract. Applying a Ves v 5-spiked YJV
ImmunoCAP, the sensitivity was increased from 83.4 to
96.8 % whereby this increase was not accompanied by a
change in assay specificity. The Ves v 5-spiked YJV
ImmunoCAP (i3) is now the commercially available standard
product for one of the major allergy immunoassay suppliers
[60••, 79]. In addition to the underrepresentation of Ves v 5 in
the venom extract, other putative mechanisms for the reduced
Table 2 Examples of sIgE profiles in extract-based versus molecular diagnostics of honeybee and yellow jacket venom allergy, together with the
deduced consequence for the decision on VIT based on the sIgE assay results
sIgE of patients
1 2 3 4 5 6
Extract-based diagnostics
HBV + + + − + −
YJV + + + − + −
Relevant venom HBV/YJV HBV/YJV HBV/YJV No HBV/YJV No
Molecular diagnostics
Api m 1 + + − − − −
Api m 3 + − − + + −
Api m 4 − − − − + −
Api m 10 + − − + + −
Ves v 1 − + + − − −
Ves v 5 − + + − − +
CCD + + + − + −
Relevant venom HBV HBV/YJV YJV HBV HBV YJV
CCD cross-reactive carbohydrate determinant, HBV honeybee venom, YJVyellow jacket venom
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immunoreactivity could be an inefficient coupling of Ves v 5
to the solid phase of the assay or the masking of epitopes of the
allergen by specific ligands which are present in the natural
insect venom extract (Fig. 1c).
If a similar phenomenon also holds true for other venom
allergens is not known so far. Furthermore, the example of the
predominance of particular allergens such as Api m 1 and Api
m 4 in HBV extract creates very likely a diagnostic informa-
tion bias by favoring the detection of high abundant allergens
in natural venom extracts. Recently, an underrepresentation or
complete lack of the major allergens Api m 3 and Api m 10
was demonstrated for several therapeutic venom preparations
which are licensed in European countries for routine venom
immunotherapy [35••]. On the contrary, both allergens are
detectable in crude venom. Thus, it is possible that down-
stream processing of the venom for immunotherapy medica-
tions affects the representation of major venom allergens,
which can result in the loss of particular low abundance aller-
gens with high clinical relevance. If this also is true for diag-
nostic products using venom extracts remains speculative at
this point. However, most if not all of these aforementioned
problems can be overcome by the use of an appropriate selec-
tion of recombinant venom allergens on molecular IgE diag-
nostic assay platforms (Fig. 1b, c).
Although controversially discussed [80–82], molecular di-
agnostics with other recombinant allergens than Ves v 5 seems
to be useful for the improved detection of extract-negative
patients [80, 81] depending on the quality of allergens used
and the sensitivity of the assay platform [80, 83]. Additionally,
we found that molecular diagnostics together with a diagnostic
cut-off of 0.1 kU/L might be useful for the diagnosis of pa-
tients with low or undetectable sIgE to venom extract, espe-
cially for those with mastocytosis and/or elevated baseline
serum tryptase, and can lead to a diagnostic sensitivity of
100 % for patients with YJVallergy (unpublished data).
Molecular Diagnostics for the Prediction of Therapy
Success
Apart from a well-documented field sting without a systemic
reaction, the only recommended diagnostic method for the
prediction of success of venom immunotherapy is the sting
challenge with a living insect [84]. Most patients who are still
reacting to a sting challenge while receiving conventional Hy-
menoptera venom immunotherapy will be protected by in-
creased venom maintenance dosages [85, 86], whereby treat-
ment failure rates are higher in patients suffering from bee
venom allergy than from yellow jacket venom allergy [87•].
Since sting challenge tests can elicit severe systemic reactions,
adequate in vitro methods for the prediction of success of
immunotherapy would be more desirable. It appears possible
that IgE analyses using molecular venom allergens might help
to identify patients who are at risk to incompletely respond to
conventional VIT. A possible consequence for those patients
would be to initiate VIT already at a higher maintenance dos-
age from the very beginning and/or to apply specific compan-
ion diagnostics to them, such as sIgG4 measurements using
recombinant venom allergens. As mentioned above the major
HBV allergens Api m 3 and Api m 10, to which more than
50 % of HBVallergic patients exhibit significant IgE reactiv-
ity, are underrepresented or missing in several of the licensed
HBV preparations routinely used for VIT [35••, 41••]. Of 144
patients with confirmed HBV allergy, 68 % showed sIgE re-
activity with Api m 3 and/or Api m 10 and 4.8 % were sensi-
tized to Api m 3 and/or Api m 10 exclusively [41••]. More-
over, in patients undergoing HBV VIT, a robust induction of
allergen-specific IgG4 was observed to the highly abundant
allergens Api m 1 and Api m 4, at a level comparable to with
the specific IgG4 against whole venom extract. In contrast, a
substantially lower induction of specific IgG4 to Api m 3 and
Api m 10 was detected in the same study [41••]. So far, it
remains speculative whether the lack of these particular aller-
gens in certain therapeutic HBV preparations is a major factor
contributing to the previously observed reduced efficacy of
HBV VIT or whether other factors exist that still need to be
identified. This hypothesis of the existence of potential sIgE
sensitizations, which could be associated with a higher risk of
therapeutic failure in HBV VIT, is currently under further
clinical investigation by applying all the recent developments
in the field of molecular sIgE diagnostics (personal commu-
nication Prof. P. Schmid-Grendelmeier, Zurich, Switzerland).
Conclusions
Already today, molecular sIgE diagnostics of Hymenoptera
venom allergy represent more than just an advanced diagnos-
tic strategy. It has created added clinical value over the last
decade. A component-resolution based on recombinant CCD-
free species-specific allergens enables the differentiation be-
tween true sensitization and cross-reactivity and thus, in many
patients improves the selection of the appropriate venom im-
munotherapy or the unnecessary therapy with multiple
venoms instead of a single venom. Additionally, the availabil-
ity of recombinant allergens facilitates to bypass the inherent
limitations of venom extracts caused by heterogeneity and
underrepresentation of particular important allergens. More-
over, for the future, component-resolved analyses possess the
potential to improve the longitudinal monitoring of patients in
the course of VIT on the level of sIgE and/or sIgG1/4 to
molecular allergens. Further clinical studies will have to dem-
onstrate, whether these new diagnostic tools will indeed pro-
vide superior diagnostic information to the clinician in charge
of the venom-allergic patient, thus enabling the a priori
26 Page 8 of 11 Curr Allergy Asthma Rep (2015) 15: 26
identification of patients, at risk to inadequately respond to
conventional extract-based venom immunotherapy.
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